Lanton Law Blog — Lanton Law

Lanton Law's Webinar With WellSky Now Available

Our recently recorded webinar with WellSky is now available.

healthcare, home infusion, life sciences, pharmaceuticals, pharmacyRon LantonNovember 25, 2019biosimilars, home health, home infusion

New Lanton Law Webinar on December 4th with the American College of Apothecaries (ACA)

We have a new webinar on December 4, 2019 via the American College of Apothecaries (ACA) on CBD.

Congress, healthcare, life sciences, pharmaceuticals, pharmacyRon LantonNovember 25, 2019CBD, FDA, DEA, Congress, 2018 Farm Bill

What's Next for DIR Policy?

We have a new article in the American College of Apothecaries (ACA) titled “What’s Next for DIR Policy?”

healthcare, life sciences, pharmaceuticals, pharmacyRon LantonNovember 25, 2019pharmacy, Pharmacy Benefit Manager

More Data Oversight on the Horizon

No matter what, technology will always move faster than the law. With this maxim and our ever increasing reliance on convenient information, we have seen technology companies try to bring us what we want to see while also collecting a staggering amount of information on consumers. With regulations scant on personal data, Congress is slowly becoming more active in making policy governing technology.

The Specialty Pharmacist's Role in Educating Patients about Biosimilars and Biologics

Ron Lanton III, Esq. of Lanton Law discusses with Specialty Pharmacy Times the specialty pharmacist's role in educating patients about biosimilars and biologics

New Administration Rules Seek Healthcare Cost Transparency

With the release of the Administration’s American Patient’s First Blueprint in May 2018, price transparency was shown to be a centerpiece of the Administration’s governing agenda. Last week, the Administration released two rules, each at different points of the rulemaking process.

life sciences, pharmaceuticals, pharmacy, healthcare, CMSRon LantonNovember 17, 2019insurance, hospital

New PBM Legislation Advances in Congress

Congresswoman Amy Spanberger (D-VA) has sponsored H.R. 2115 titled “Public Disclosure of Drug Discounts and Real-Time Beneficiary Drug Cost Act.” This is important for healthcare stakeholders, as this proposed legislation requires greater transparency for discounts provided by manufacturers. This bill also proposes to include real-time benefit information as part of a prescription drug plan’s electronic prescription program under Medicare.

healthcare, life sciences, pharmaceuticals, pharmacyRon LantonNovember 8, 2019Pharmacy Benefit Manager

Setting the Record Straight on March-In Rights and Drug Prices

Following the launch of sofosbuvir (Sovaldi) in 2013, the pharmaceutical industry has been in the crosshairs of the government because of the drug's cost. Many industry stakeholders have been wrestling with difficult questions: How should the fair value of a drug be determined? What should the cost be for better outcomes? How much should a drug cost if it extends life? We have seen some political solutions advanced, such as the International Pricing Index, the Rebate Rule, and others, but no silver bullet to controlling costs has manifested to date.

healthcare, life sciences, pharmaceuticalsRon LantonNovember 3, 2019Congress, march-in rights

The Specialty Pharmacist's Role in Educating Patients about Biosimilars and Biologics

Ron Lanton III, Esq., discusses the specialty pharmacist's role in educating patients about biosimilars and biologics.

healthcare, life sciences, pharmacy, pharmaceuticalsRon LantonNovember 3, 2019biologics, biosimilars, pharmacy, specialty pharmacy

The Challenges to Launching Biosimilars

Check out Ron Lanton’s interview with Specialty Pharmacy Times on “The Challenges to Launching Biosimilars” https://www.pharmacytimes.com/news/challenges-to-launching-biosimilars

healthcare, life sciences, pharmacy, home infusionRon LantonOctober 24, 2019biosimilars, biologics

Is the Insulin Price Reduction Act the Right Answer to High Insulin Prices?

At this point in the legislative calendar, it is time to take a look at what may have a likely shot at passing Congress before the 2020 election season gets underway. With the contentious debate on drug pricing that has occurred during the last several months, insulin pricing is still garnering plenty of attention.

Cannabidiol Made Simple

Cannabidiol (CBD) has certainly drawn significant attention over the past few months. Marked by the recent passage of the Farm Bill and the FDA’s hearing on CBD at the end of May, the curiosity about and demand for the products have never been stronger. Unfortunately, misinformation on the effects of CBD remains rampant, including details on whether combining CBD with food affects the body’s absorption and conflicting reports on the various differences in state regulation.

healthcare, life sciencesRon LantonOctober 18, 2019CBD, FDA, DEA, 2018 Farm Bill, USDA, Epidiolex

How Will the United States–Mexico–Canada Agreement Affect Biosimilars?

For years we have witnessed the fierce debate over whether the North American Free Trade Agreement (NAFTA) is serving the best interests of the United States. In following up on a 2016 campaign promise to renegotiate NAFTA, the new NAFTA, called the United States–Mexico–Canada Agreement (USMCA), is currently being debated by Congress, and there are concerns as to whether the agreement will be ratified.

healthcare, life sciences, tradeRon LantonOctober 18, 2019Congress, biologics, biosimilars, USMCA

2 Bills, 1 Goal: Lower Drug Prices Through Biosimilars

Just prior to an election season, it is not surprising to see a few bills emerge as potential silver bullets to solve pressing policy issues. The latest issue that has consumed the public for several years is how to lower drug prices. While policymakers have raised a series of threats to the industry, such as having Medicare negotiate drug prices, getting rid of drug rebates, and the specter of importation, none of these threats have yet to materialize into any meaningful legislation. What has remained consistent is the intrigue of biosimilars and whether finding ways to increase their utilization in the market could provide the elusive key to lowering drug costs. Two Congressional bills have recently emerged illustrating this desire.